Safety Profiles Compared: Both Available for Same-Day Order
Which Is Safer Wegovy or Mounjaro - Clinical Safety Data Available Now
When evaluating which is safer between Wegovy and Mounjaro, both medications demonstrate established safety profiles from extensive clinical trials. Wegovy's safety data comes from the STEP programme involving over 4,500 participants, whilst Mounjaro's evidence derives from the SURMOUNT trials with similar participant numbers. Both are prescription-only medicines requiring careful medical supervision and regular monitoring.
The availability of both treatments at EverydayMeds means you can discuss safety considerations with our prescribers without supply constraints affecting your choice. Our GPhC-registered pharmacy (#9012878) maintains full stock levels of all Wegovy doses, ensuring your safety-focused decision isn't compromised by availability issues that have historically affected UK supplies.
Wegovy and Mounjaro In Stock UK - Pricing and Treatment Value
Understanding which is safer between Wegovy and Mounjaro includes considering treatment accessibility and value. Wegovy starts at £79.99 for the 0.25mg starter dose with new customer code FIRST40 applied at checkout, progressing through a structured escalation to £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles like the Intro Duo (0.25mg & 0.5mg) cost £169.99, providing your first 8 weeks of treatment in one convenient order.
Returning customers benefit from the DOSE25 discount code, with our Ultimate Stability Trio offering three months of 2.4mg maintenance supply for £649.99. Both Wegovy and Mounjaro follow similar pricing structures, though Wegovy offers the practical advantage of 6 weeks room temperature storage compared to Mounjaro's 21 days, potentially affecting long-term treatment costs and convenience.
Clinical Evidence: Which Is Safer Wegovy or Mounjaro Based on Trial Data
Wegovy's safety profile from the STEP trials shows gastrointestinal side effects as the most common, with nausea affecting approximately 44% of participants compared to 5% on placebo (Wilding et al., NEJM, 2021). Most side effects were mild to moderate and decreased over time as patients adapted to treatment.
Mounjaro's SURMOUNT trials demonstrated similar gastrointestinal tolerability patterns, though direct head-to-head safety comparisons aren't available due to different trial designs and populations. Both medications carry similar contraindications and require careful monitoring for rare but serious side effects including pancreatitis and gallbladder disorders.
How Wegovy Works - Understanding the Safety Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormones to reduce appetite and promote satiety after smaller meals. This targeted mechanism works primarily on brain appetite centres, potentially reducing food cravings whilst slowing gastric emptying to extend feelings of fullness. The once-weekly injection schedule using Novo Nordisk's FlexTouch pen system provides consistent medication levels with minimal peaks and troughs. Understanding this mechanism helps explain why gastrointestinal side effects occur initially as your digestive system adapts to slower food transit times. The gradual dose escalation protocol from 0.25mg to 2.4mg over 16 weeks is specifically designed to minimise side effects whilst optimising therapeutic benefits.
Ordering Process - Same-Day Assessment for Both Treatment Options
Our streamlined process ensures you can access either Wegovy or Mounjaro quickly and safely through proper medical channels. The 3-minute online clinical assessment covers your medical history, current medications, and weight management goals to help determine the most suitable option for your circumstances. Standard prescriber review takes 3 working days, though our express 24-hour service is available for urgent requirements. Once approved, next-day delivery uses temperature-controlled cold-chain logistics to maintain medication integrity from our GPhC-registered facility (#9012878) to your door. Both treatments require the same thorough assessment process, ensuring safety considerations are properly evaluated regardless of which option you choose.
Storage and Practical Safety Considerations
Wegovy offers a practical safety advantage with 6 weeks of room temperature storage (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day limit. This extended stability reduces risks of medication degradation during travel or temporary storage issues, potentially affecting treatment safety and efficacy. The FlexTouch pen system includes safety features like automatic needle insertion and disposal requirements to minimise injection-related risks. Proper storage at 2-8°C before first use maintains medication potency and reduces contamination risks. The structured dose escalation schedule helps your healthcare provider monitor tolerance and adjust treatment if safety concerns arise during the titration period.
Which Is Safer Wegovy or Mounjaro - Individual Risk Assessment Available
Determining which is safer between Wegovy and Mounjaro requires individual risk assessment considering your specific medical history, concurrent medications, and treatment goals. Both medications require similar monitoring for rare but serious adverse effects including thyroid tumours (though no causal relationship established in humans) and potential pancreatitis. Your medical history of gallbladder disease, kidney problems, or diabetic retinopathy may influence which option presents lower individual risk.
EverydayMeds prescribers can evaluate your complete medical profile to recommend the most appropriate option based on current safety data and your personal risk factors. Having both treatments readily available means your safety-focused choice isn't constrained by supply limitations that could force suboptimal treatment decisions.
Complete Your Assessment - Both Options Available Today
Start your clinical assessment today knowing both Wegovy and Mounjaro remain in stock for immediate processing once approved by our medical team. New customers use code FIRST40 at checkout, whilst returning customers apply DOSE25 to access our competitive pricing structure. Our comprehensive stock holding across all Wegovy doses from 0.25mg starter through 2.4mg maintenance ensures continuity of care throughout your treatment journey. Both medications are available from EverydayMeds with the same high standards of pharmaceutical care and clinical oversight. Complete your assessment now to begin your medically supervised weight management programme with confidence in both safety and supply reliability.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
